Associate Professor of Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Daniel J. Deangelo, MD
|
|
Give Review
Daniel J. Deangelo, MD practices Hematology. He attended Albert Einstein College of Medicine of Yeshiva University. He has 1 awards "Regional Top Doctor". Daniel Deangelo is a published physician as well. He has 92 publications published. The latest was: Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Daniel Deangelo accepts Medicare payments and is listed with Medicare.gov.
Publications
- Pediatric-inspired therapy compared to alloGrafting for Philadelphia chromosome-negative adult ALL in first complete remission.
- HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell Acute lymphoblastic leukemia.
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed Acute lymphoblastic leukemia.
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with Acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory Acute myeloid leukemia and myelodysplastic syndromes.
- The role of Lin28b in Myeloid and mast cell differentiation and mast cell malignancy.
- One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid Leukemia: a matching-adjusted indirect comparison.
- Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell Acute lymphoblastic leukaemia.
- De novo Acute myeloid leukemia with 20-29% blasts is less aggressive than Acute myeloid leukemia with â¥30% blasts in older adults: A Bone Marrow Pathology Group study.
- Switching drugs midstream for patients with chronic myeloid Leukemia.
- The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling.
- A genome-wide aberrant RNA splicing in patients with Acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.
- NOTCH2 and FLT3 gene mis-splicing are common events in patients with Acute myeloid leukemia (AML): new potential targets in AML.
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.
- Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia.
- Recombinant interleukin-2 in patients aged younger than 60 years with Acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.
- AZD1208, a potent and selective pan-pim kinase inhibitor, demonstrates efficacy in preclinical models of Acute myeloid leukemia.
- A phase II study of the EGFR inhibitor gefitinib in patients with Acute myeloid leukemia.
- Chronic myelogenous Leukemia, version 1.2014.
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias.
- Geriatric assessment in older patients with Acute myeloid leukemia: a retrospective study of associated treatment and outcomes.
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
- Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.
- Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with Acute promyelocytic leukemia.
- Phase II trial of panobinostat, an Oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera ...
- SYK regulates mTOR signaling in AML.
- Resistance revealed in Acute lymphoblastic leukemia.
- Phase Ia/II, 2-arm, open-label, dose-escalation study of Oral panobinostat administered via 2 dosing schedules in patients with advanced hematologic malignancies.
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response crite...
- Dose intensification of daunorubicin and cytarabine during treatment of adult Acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Ac...
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML.
- Detecting T-Cell reactivity to whole Cell vaccines: Proof of concept analysis of T-Cell response to K562 Cell antigens in CML patients.
- Chronic myelogenous Leukemia. Clinical practice guidelines in oncology.
- Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
- Chronic myeloid Leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms...
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
- Candida albicans cervical lymphadenitis in patients who have Acute myeloid leukemia.
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal Acute myeloid leukemia (CN-AML) and FLT3ITD.
- Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory Acute myeloid leukemia.
- An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple Myeloma.
- Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with Acute myeloid leukem...
- Invasive fungal disease in patients treated for newly diagnosed Acute leukemia.
- NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on ...
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell Disease.
- When to go FISHing.
- Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk Acute myeloid leukemia.
- Functional screening identifies CRLF2 in precursor B-cell Acute lymphoblastic leukemia.
- Proteomic and genetic approaches identify Syk as an AML target.
- Nelarabine for the treatment of patients with relapsed or refractory T-cell Acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Screens, iron, and Leukemia.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting Cellular immunotherapy in combination with autologous stem Cell transplantation (ASCT) as postremis...
- A forgotten cause of kidney injury in chronic myelomonocytic Leukemia.
- Identification of AML1-ETO modulators by chemical genomics.
- Allogeneic stem cell transplantation for Acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
- Low dose interleukin-2 following intensification therapy with high dose cytarabine for Acute myelogenous leukemia in first complete remission.
- Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B Acute lymphocytic leukemia.
- Progressive multifocal leukoencephalopathy in a patient with relapsed Acute myelogenous leukemia.
- Recurrent Acute promyelocytic leukemia presenting as a sacral nerve root mass.
- New agents for the treatment of patients with Acute lymphoblastic leukemia.
- Clinical problem-solving. A joint venture.
- Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations.
- Optimizing outcomes for patients with advanced disease in chronic myelogenous Leukemia.
- Alu elements mediate MYB gene tandem duplication in human T-ALL.
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage Acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Grou...
- Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
- Favorable outcome for adolescents with Acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
- Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in Myeloid cell transformation.
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with Acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, ...
- Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced Acute myelogenous leukemia and myelodysplastic syndrome.
- Systemic mastocytosis: current classification and novel therapeutic options.
- MPLW515L is a novel somatic activating mutation in myelofibrosis with Myeloid metaplasia.
- Gefitinib induces myeloid differentiation of Acute myeloid leukemia.
- Isochromosome of a deleted 20q may be a relatively common abnormality in Myeloid malignancies.
- Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome?
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic Cell transplantation for patients older than 50 years of age.
- After chronic myelogenous Leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
- Patients with Acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
- The treatment of adolescents and young adults with Acute lymphoblastic leukemia.
- PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem Cell myeloproliferative disorder.
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
- Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous Leukemia relapse after allogeneic transplantation: durable cytogenetic ...
- Imatinib therapy for patients with chronic myelogenous Leukemia: are patients living longer?
- Fatal hepatic necrosis following imatinib mesylate therapy.
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive Disease in patients who undergo myeloablative allogeneic stem cell transplantat...
- PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative Disease.
- A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
- Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous Leukemia.
- Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.
- A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia.
Schools
Albert Einstein College of Medicine of Yeshiva University
Ma Genl Hospital
Dana Farber Cancer Institute
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur T. Skarin, MD |
|
|
Dr. Judy E. Garber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Bradner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary-Ellen Taplin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Kala Seetharaman, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonardo A. Sirulnik, MD |
|
|
Dr. Jennifer R. Brown, MD |
|
|
Dr. Joseph H. Antin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Edwin P. Alyea III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zachary S. Spigelman, MD
This Doctor is OpenDoctor Recommended.
|